Windlas Biotech Limited is among the top five players in the domestic pharmaceutical formulations contract development and manufacturing organization (CDMO) industry in India in terms of revenue (Source: CRISIL Report). With over two decades of experience in manufacturing both solid and liquid pharmaceutical dosage forms, along with significant expertise in providing specialized capabilities, including high potency, controlled substances, and low-solubility products, they offer a comprehensive range of CDMO services. These services include product discovery, product development, licensing, and commercial manufacturing of generic products, including complex generics, all in compliance with current Good Manufacturing Practices (GMP), with a focus on improving safety, efficacy, and cost. In Fiscal 2020, their market share was approximately 1.5% in terms of revenue in the domestic formulations CDMO industry (Source: CRISIL
Windlas Biotech Limited is among the top five players in the domestic pharmaceutical formulations contract development and manufacturing organization (CDMO) industry in India in terms of revenue (Source: CRISIL Report). With over two decades of experience in manufacturing both solid and liquid pharmaceutical dosage forms, along with significant expertise in providing specialized capabilities, including high potency, controlled substances, and low-solubility products, they offer a comprehensive range of CDMO services. These services include product discovery, product development, licensing, and commercial manufacturing of generic products, including complex generics, all in compliance with current Good Manufacturing Practices (GMP), with a focus on improving safety, efficacy, and cost. In Fiscal 2020, their market share was approximately 1.5% in terms of revenue in the domestic formulations CDMO industry (Source: CRISIL Report). In addition to providing services and products in the CDMO market, they also sell their own branded products in the trade generics and OTC markets, as well as export generic products to several countries. The prevalence of chronic diseases in India has been increasing in recent years, particularly in key therapeutic categories such as anti-diabetic, cardiovascular, neuropsychiatry, and respiratory therapies, which are treated with 'multi-drug therapy' by physicians, i.e., the specific use of two or more drugs for single or multiple chronic conditions in an individual. Moreover, multi-drug therapy has gained importance in the healthcare sector and is expected to contribute to the growth of pharmaceutical consumption (Source: CRISIL Report).
Show More